Inside Precision Medicine January 24, 2025
Genetic research has revealed that popular weight loss medication in the form of glucagon-like peptide 1 receptor agonists (GLP1RAs) is unlikely to directly affect behavior through its impact on the cardiometabolic system.
The UK Biobank study, published in the journal Diabetes, Obesity and Metabolism, showed that links to mental health were unlikely to happen through the GLP1 receptor (GLP1R).
Genetic variants in the GLP1R gene had consistent associations with body mass index, blood pressure, and Type 2 diabetes among people of different ethnic backgrounds in the study.
But the genetic variants affecting these cardiometabolic traits (CMts) differed to those linked with behavioral changes such as risk taking and were separate to those that affected GLP1R gene expression.
“Whilst it is...
Today's Sponsors
Today's Sponsor